Phaseline

Companies › Karyopharm Therapeutics

Karyopharm Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 103 registered trials: 58 Phase 2, 32 Phase 1, 11 Phase 3, 2 Phase 4; Hematology, Oncology, Genitourinary, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Selinexor (KPT-330)
Exportin-1 inhibitor
XPO1Phase 3Endometrial Cancer; Myelofibrosis; Diffuse Large B-cell Lymphoma; Relapsed/Refractory Diffuse Large B-cell Lymphoma …Dec 2026
Bortezomib
26S proteasome inhibitor
PSMD1, PSMB2, PSMB1, PSMB5, PSMB8Phase 2Multiple Myeloma, Refractory; Hematological Neoplasms; Newly Diagnosed; Multiple Myeloma …Jan 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT00492050BortezomibPhase 2Waldenstrom's MacroglobulinemiaOncologyFeb 2021
NCT06853080BortezomibPhase 2Atypical Teratoid/Rhabdoid Tumors (AT/RTs)OncologyDec 2023
NCT05597345Selinexor (KPT-330)Phase 2Smoldering Multiple MyelomaOncologyOct 2024
NCT03589222Selinexor (KPT-330)Phase 2Refractory Multiple MyelomaOncologyAug 2026
NCT03589222BortezomibPhase 2Refractory Multiple MyelomaOncologyAug 2026
NCT04562870Selinexor (KPT-330)Phase 2MyelofibrosisOncologySep 2026
NCT04925193Selinexor (KPT-330)Phase 2Multiple Myeloma in RelapseOncologyNov 2026
NCT06559553Selinexor (KPT-330)Phase 1NKTCLOncologyDec 2026
NCT05979363BortezomibPhase 2Plasma Cell LeukemiaOncologyDec 2026
NCT02227251Selinexor (KPT-330)Phase 2Diffuse Large B-cell LymphomaOncologyDec 2026
NCT04442022Selinexor (KPT-330)Phase 2Relapsed/Refractory Diffuse Large B-cell LymphomaOncologyDec 2026
NCT02091245Selinexor (KPT-330)Phase 1Relapsed Acute Lymphoblastic Leukemia (ALL)OncologyDec 2026
NCT01208662BortezomibPhase 3Multiple MyelomaOncologyDec 2026
NCT06029998BortezomibPhase 2Metastatic Castration-resistant Prostate CancerOncologyDec 2026
NCT06342466BortezomibPhase 2Systemic AmyloidosisMetabolic and endocrineDec 2026
NCT00378105BortezomibPhase 1Multiple MyelomaOncologyDec 2026
NCT03643549BortezomibPhase 1GlioblastomaOncologyDec 2026
NCT05833893Selinexor (KPT-330)Phase 2nk/T-cell LymphomaOncologyDec 2026
NCT06822972Selinexor (KPT-330)Phase 2Multiple Myeloma in RelapseOncologyDec 2026
NCT05698147Selinexor (KPT-330)Phase 1Central Nervous System LymphomaOncologyDec 2026
NCT03844360BortezomibPhase 4Hematological NeoplasmsOncologyDec 2026
NCT01863550BortezomibPhase 3Plasma Cell MyelomaOncologyDec 2026
NCT03993262BortezomibPhase 2Autoimmune EncephalitisImmunologyDec 2026
NCT06418477BortezomibPhase 2Monoclonal Gammopathy of Renal SignificanceGenitourinaryDec 2026
NCT05514990BortezomibPhase 1Recurrent Plasma Cell MyelomaOncologyDec 2026
NCT07369739Selinexor (KPT-330)Phase 2LymphohistiocytosisHematologyJan 2027
NCT04991103BortezomibPhase 2Multiple MyelomaOncologyJan 2027
NCT06517511Selinexor (KPT-330)Phase 2Diffuse Large B Cell LymphomaOncologyJan 2027
NCT05736419BortezomibPhase 2Sickle Cell DiseaseHematologyFeb 2027
NCT03620903BortezomibPhase 2Waldenstrom MacroglobulinemiaOncologyFeb 2027
NCT01695941BortezomibPhase 1Recurrent B-Cell Non-Hodgkin LymphomaOncologyMar 2027
NCT05736978Selinexor (KPT-330)Phase 2AMLOncologyMar 2027
NCT01861314BortezomibPhase 1Acute Myeloid LeukemiaOncologyMar 2027
NCT02343042Selinexor (KPT-330)Phase 1Multiple MyelomaOncologyApr 2027
NCT05870917BortezomibPhase 2Plasma Cell LeukemiaOncologyApr 2027
NCT02835222Selinexor (KPT-330)Phase 2Untreated Adult Acute Myeloid LeukemiaOncologyApr 2027
NCT05736965Selinexor (KPT-330)Phase 2AML, AdultOncologyApr 2027
NCT05333458Selinexor (KPT-330)Phase 2Advanced Alveolar Soft Part SarcomaOncologyMay 2027
NCT06966154Selinexor (KPT-330)Phase 1Natural Killer/T-cell LymphomaOncologyMay 2027
NCT00644228BortezomibPhase 3DS Stage I Multiple MyelomaOncologyJun 2027
NCT05980806Selinexor (KPT-330)Phase 2MyelofibrosisHematologyJun 2027
NCT05980806Selinexor (KPT-330)Phase 2MyelofibrosisHematologyJun 2027
NCT03147885Selinexor (KPT-330)Phase 1Diffuse Large B-Cell LymphomaOncologyJun 2027
NCT05432804Selinexor (KPT-330)Phase 1Recurrent Glioblastoma, IDH-WildtypeOncologyJun 2027
NCT07094464Selinexor (KPT-330)Phase 1TP53-mutated MDS and AMLOncologyJun 2027
NCT04915248BortezomibPhase 2Plasmablastic LymphomaOncologyJul 2027
NCT07479979Selinexor (KPT-330)Phase 1Relapse Multiple MyelomaOncologyJul 2027
NCT05470491BortezomibPhase 1HIVOncologyJul 2027
NCT03136146BortezomibPhase 2Recurrent Acute Lymphoblastic LeukemiaOncologyAug 2027
NCT05665140BortezomibPhase 2Newly Diagnosed Multiple MyelomaOncologyAug 2027
NCT04898894Selinexor (KPT-330)Phase 1Acute Leukemia of Ambiguous Lineage in RelapseOncologySep 2027
NCT02112916BortezomibPhase 3Adult T Acute Lymphoblastic LeukemiaOncologySep 2027
NCT06169215Selinexor (KPT-330)Phase 2Multiple MyelomaOncologySep 2027
NCT06169215BortezomibPhase 2Multiple MyelomaOncologySep 2027
NCT05099003Selinexor (KPT-330)Phase 1Malignant GliomaOncologySep 2027
NCT03763162BortezomibPhase 2Recurrent Plasma Cell MyelomaOncologyOct 2027
NCT05035745Selinexor (KPT-330)Phase 1Advanced Refractory Solid TumorsOncologyNov 2027
NCT06409702BortezomibPhase 4Newly DiagnosedOncologyNov 2027
NCT04775550BortezomibPhase 2High-risk Smoldering Multiple MyelomaOncologyDec 2027
NCT04756401Selinexor (KPT-330)Phase 2Recurrent Plasma Cell MyelomaOncologyDec 2027

The 60 nearest readouts of 103 trials; the rest in the app.

From the company's SEC filings

Cash and short-term investments of $65m on 2026-06-30; operating cash outflow about $97m a year; runway about 8 months at that burn, to Mar 2027; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

XPO1 (1) PSMD1 (1) PSMB2 (1) PSMB1 (1) PSMB5 (1) PSMB8 (1)

Companies with the same targets

Pfizer Regeneron Pharmaceuticals

Companies built like this

Geron Aura Biosciences Disc Medicine Kind Pharmaceuticals Dogwood Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.